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ABSTRACT 
Levamisole-contaminated cocaine is an increasingly reported cause of a syndrome characterized by 
vasculitic skin lesions and immunologic abnormalities. With approximately 70% of cocaine in the 
United States now contaminated with levamisole, the incidence of this syndrome is likely to 
increase. We report the case of a 42 years-old Caucasian woman who presented with fronto-
temporal pulsating headache and progressive bilateral loss of vision.  
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INTRODUCTION 
Levamisole-contaminated cocaine is an increasingly reported cause of a syndrome characterized by 
vasculitic skin lesions and immunologic abnormalities. With approximately 70% of cocaine in the 
United States now contaminated with levamisole, the incidence of this syndrome is likely to 
increase. 
CASE REPORT 
We report the case of a 42 years-old Caucasian woman who underwent our observation due to 
fronto-temporal pulsating headache and progressive bilateral loss of vision with inability to see in 
dim light or at night (nyctalopia), lasting for one month. Medical and social history was positive for 
chronic cocaine abuse, high alcohol intake, previous right retinal hemorrhage and hospitalization for 
pericarditis and paroxysmal supraventricular tachycardia. Neurological examination resulted in 
normal findings except for bilateral tunnel vision (Figure 1). The patient underwent brain CT, MRI 
and magnetic resonance angiography (angio MRI) which were within normal limits (Figure 2). 
Additionally, maxillofacial CT was performed showing chronic sinusitis and chronic 
parodontopathy, resulting from previous nasal septum perforation. Visual field testing showed 
bilateral centrocecal scotomas. Nasal septum biopsy showed necrosis and chronic mucositis. 
Optical coherence tomography displayed bilateral thinning of temporal fibers. Blood exams showed 
high titer of ANCA antibodies: pANCA/MPO, 85.7 (normal values negative); ANA 1:80 (normal 
values negative); slight increase of ESV of 50 mm (normal range 1-32mm), RCP of 70.1 (normal 
value <5). Both complete blood count and renal function parameters were normal. Urine 
toxicological tests were positive for cocaine. Levamisole was not tested. 
Prednisone 1mg/kg/daily was initiated. After one month of therapy there was an improvement in the 
general condition an improvement of general condition with consequent reduction of the dose. The 
patient was devoid of cocaine during the therapy. 
 
DISCUSSION 
Levamisole is a synthetic imidazothiazole derivative which was originally marketed as an 
anthelmintic agent but was also found to have major immunomodulatory properties (1). It induced 
interferon synthesis and synergized the effect of steroids and other immunosuppressants (2). It was 
used in cancer therapy such as colon and breast cancer, or to treat various immunological renal 
diseases, such as pediatric nephrotic syndrome. Further, it was used to treat a number of skin 
diseases, including Behçet's disease and rheumatoid arthritis. However, the drug was withdrawn 
from the market in the United States in 2000 and in Canada in 2003 because of serious side effects. 
It is still available as a veterinarian deworming drug in the United States and South America (2, 3).  
The mechanism of action of levamisole as an antiparasitic agent appears to be tied to its agonistic 
activity towards the L-subtype nicotinic acetylcholine receptors in nematode muscles. This 
agonistic action reduces the capacity of the males to control their reproductive muscles and limits 
their ability to copulate (4).  
The effects of levamisole on the immune system are complex. The drug appears to restore 
depressed immune function rather than to stimulate response to above-normal levels (4). 
Levamisole can stimulate formation of antibodies to various antigens, enhance T-cell responses by 
stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions 
including phagocytosis and chemotaxis, and increase neutrophil mobility, adherence, and 
chemotaxis (5).  
Levamisole is readily absorbed from the gastrointestinal tract and metabolized in the liver. It 
achieves peak plasma concentration is 1.5–2 hours (6). Its plasma elimination half-life is 3–4 hours, 
which is fairly short and may often be the reason for negative toxicological tests that detect 
levamisole (7). Levamisole rapidly metabolizes to aminorex and related metabolites, which have a 
half-life of about 16 hours (6, 8). Levamisole's excretion is primarily through the kidneys, with 
about 70% being excreted over 3 days (5). Only about 5% is excreted as unchanged levamisole (7). 
Aminorex is an amphetamine-like agent that was detected in racehorses after levamisole 
administration (8). Aminorex was marketed as an appetite suppressant in the mid-1960s mainly in 
Switzerland, Austria, and Germany; it was found to cause pronounced vasoconstriction in the 
pulmonary vasculature and was withdrawn in 1972 due to several cases of fatal and life-threatening 
pulmonary hypertension (8). 
Levamisole has also been recognized as an adulterant in illicit cocaine since 2003. A 2009 national 
survey found that approximately 70% of cocaine in the USA is contaminated with levamisole (9). It 
is added to cocaine because it potentiates its stimulant effects by inhibiting both monoamine 
oxidase and catechol-O-methyltransferase activity, thereby prolonging the action of catecholamines 
in theneuronal synapse and increasing the reuptake-inhibition effect of cocaine (4).   
The concentration of levamisole in cocaine has steadily increased since it was first detected. The 
concentration was less than 1% in 2001, and in 2009, levamisole comprised approximately 10% of 
each cocaine sample. In an analysis of cocaine users in Seattle, Washington, approximately 80% of 
users who tested positive for cocaine also tested positive for levamisole (10). Levamisole is also 
used to adulterate other illicit substances; seized heroin supplies in 2008 and 2009 were found to 
contain trace amounts of levamisole (10). 
Also aminorex was detected in human urine samples in a multitude of cocaine abusers. It seems to 
exert strong effects on all three neurotransmitter monoamine transporters serotonin (SERT), 
norepinephrine (NET) and dopamine (DAT) in a manner similar to amphetamine (8). 
Levamisole-induced vasculitis was first described in the 1970s (11). Levamisole-induced vasculitis 
is a cutaneous vasculitis that has been reported with smoked crack cocaine and inhaled cocaine 
powder. It has a greater frequency in women (male to female ratio 1:3), with a mean age of 
presentation of 44 years (1, 11). It is characterized by skin involvement, especially necrotic purpura 
located in the ears, leukoneutropenia, ANCAs and/or APL Abs and good prognosis on levamisole 
cease.  Although other compounds can be added to cocaine, vasculitis has been associated with 
long-term use of cocaine mixed with stimulants such as levamisole (12). Patients with LIV develop 
tender purpuric lesions 1 to 3 days after exposure (12). These lesions first develop as symmetric 
erythema, evolve into retiform purpura, bullae, and finally undergo necrosis and eschar formation 
(12). Most commonly, lesions develop over the ear, malar eminences, and tip of the nose. Diagnosis 
of LIV is on its clinical presentation and histopathological findings of leukocytoclastic vasculitis of 
small vessels containing fibrinous necrosis of the vessel wall, erythrocyte extravasation, and 
multiple fibrin thrombi within small vessels in the superficial and deep dermis (12). 
Other recognized manifestations among cocaine abusers are pulmonary-renal syndrome (13), 
multifocal recurrent leukoencephalopathy with diffuse white matter involvement with sparing of the 
U fibers, without brain stem or cerebellar involvement.(14, 15), pyoderma gangrenosum (16), 
intravascular thrombosis and less commonly crescentic nephritis, retiform purpura and pauci-
immune glomerulonephritis (17, 18). Common side effects are shown in Table 1, while common 
laboratory values are presented in Table 2. 
Bilateral tunnel vision has been described in various ocular diseases, such as retinitis pigmentosa 
(RP) (19), choroideremia (20), and glaucoma (21), but has never been described before as a 
presenting sign for levamisole vasculitis. 
CONCLUSION 
We described a case of levamisole-adulterated cocaine-vasculitis with atypical symptoms of 
presentation, such as headache and bilateral tunnel vision, both improved after discontinuing 
cocaine abuse ad starting treatment with prednisone. We think that expand literature for this entity, 
helping specialists to considerate levamisole adulteration as a possible differential diagnosis when 
evaluating ocular signs in cocaine abuser patient. We think that bilateral tunnel vision can be 
considered as a manifestation of small vessel vasculitis with bilateral temporal fibers thinning, 
while headache can be considered a side effect of both chronic cocaine and levamisole abuse. 
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FIGURES 
 
 
A     B 
Figure 1. Bilateral tunnel vision in levamisole-induced vasculitis. (A) Visual field, left eye, (B) Visual 
field right eye 
 
A      B 
Figure 2. Brain MRI T2 (A) and MRI FLAIR (B) findings in levamisole-induced vasculitis 
 
 Table 1: levamisole common effects on the human body 
Levamisole manifestations Literature review 
Dermatological involvement  
Erythema elevatum diutinum-like vasculitis Ewan Ak et al 2018 
Vanishing vasculitis Ghias AAP et al 2018 
Generalized fatal vasculitis Hammond B et al 2017 
Pyoderma gangrenosum Seghal R et al 2017 
Jeong HS et al 2016 
Retiform purpura Nelson N et al 2016 
Walsh NM et al    2010 
Han C et al 2011 
Eyelid Necrosis and Secondary Cicatrical 
Ectropion 
Ramesh S et al 2017 
Delayed recurrent vasculitis with varying 
vasculitic antibodies over the years. 
Yogarajah M 2015 
Facial necrosis Formeister EJ et al 2015 
Intestinal involvement  
Ileal intussusception. van der Veer T et al 2017 
Bowel ischemia Khan et al 2018 
Osteoscheletrical involvement  
Arthralgia and myalgia van der Veer T et al 2017 
Extremity bone necrosis with amputation Ching JA 2012 
Otolaryngologic manifestation  
Otolaryngologic Manifestations Alemi AS et al 2016 
Cardiopulmonary involvement  
Acute coronary syndrome Michaud K et al 2014 
Isolated pulmonary vasculitis Karch SB 2016  
Central nervous system 
involvement 
 
Multifocal inflammatory 
leukoencephalopathy 
Vitt JR et al 2017 
Vosoughi R et al  
Recurrent leukoencephalopathy González-Duarte A et al  
Peripheral nervous system 
involvement 
 
Myopathy Tsai MH et al 2013 
Renal involvement  
Nephrotic sindrome Alvarez Diaz et al 2013 
Crescentic glomerulonephritis Chawdhary K et al 2015 
Carrara C et al 2016 
Membranous nephropathy Moinuddin I et al 2016 
Spontaneous Renal Artery Bleed Machua W et al 2016 
Pancreatic involvment  
Acute pancreatitis Ogunbameru A et al 2015 
Atypical generalized pattern  
Pseudovasculitis Fan T et al 2017 
 
Table 2: Hematological and laboratory findings in Levamisole Vasculitis 
Haematological features   
leukopenia 28% of patients Cascio ML et al 2018 
Dezman Z et al 2016 
Cherlopalle S et al 0016 
Agranulocytosis /neutropenia  Khan MS et al 2018 
Kassim T et al 2018 
Srivastava R et al 2017 
Anemia   
73% of patients 
García Pérez MR et al 2013 
Cascio ML et al 2018 
Thrombocytopenia  10% of patients Cascio ML et al 2018 
Martinez E et al 2016 
Laboratory findings   
CRP Elevated in 82.4% of patients Dartevel A 2018 
ANA Positive in 57% of patients 
raging from 1:40 to 1:1280, 
mostly homogeneous pattern 
Cascio ML et al 2018 
Anti DNA Positive in 23% of patients 
s raging from 1:10 to 1:160 
Cascio ML et al 2018 
ANCA 
 
MPO 
PR3 
Positive in 93.8% of patients 
Positive in 85% of patients 
Positive in 32.2% of patients 
Positive in 15.3% of patients 
Cascio ML et al 2018 
Dartevel A et al 2018 
Dartevel A et al 2018 
Dartevel A et al 2018 
LAC 
 
Anti cardiolipin 
 
Anti beta 2 GPI 
Positive in 42.3% of patients 
Positive in 73% of patients 
Positive in 24% (IgM), 14% 
(IgG) of patients 
Dartevel A et al 2018 
Cascio ML et al 2018 
Cascio ML et al 2018 
C3 
C4 
Both decreased in 16.1% of 
patients 
Dartevel A et al 2018 
Cryoglobulin Detected in about 19% of patients Dartevel A et al 2018 
 
CRP = C-reactive protein), ESR= Erythrocyte sedimentation Rate, ANA= anti-nuclear Ab annti DNA= anti-
deoxyribonucleic acid (anti-DNA), ANCA= anti-neutrophil cytoplasmic antibodies, anti MPO = Anti-
myeloperoxydase, PR3=  anti-proteinase 3 LAC= lupus anticoagulant, anti beta 2 GPI= anti-ß2 glycoprotein 
1, IgM = immunoglobulin M, IgG0 immunoglobulin G 
 
 
 
 
